Helex is a therapeutics company developing a new class of targeted medicines for genetic kidney diseases using its proprietary LNP drug delivery and AI-based drug design platforms. With a world-class team of scientists and drug developers, Helex operates from New York, USA, and ASPIRE BioNEST, Hyderabad, India, and is supported by Bayer Co.Lab Cambridge.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 10/30/25 | $3,500,000 | Seed |
Bluehill Capital pi Ventures  SOSV | undisclosed |
